REGENXBIO Inc. Reports Q2 2026 Financial Results

What Happened

• REGENXBIO Inc. announced results of operations and its financial condition for the quarter ended June 30, 2026 by issuing a press release on August 6, 2026. The company furnished that press release as Exhibit 99.1 to this Current Report on Form 8‑K and incorporated it by reference under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: August 6, 2026.
• Quarter covered: quarter ended June 30, 2026.
• Exhibit provided: Press release dated August 6, 2026 furnished as Exhibit 99.1.
• Form 8‑K signed by Patrick J. Christmas II, Executive Vice President, Chief Strategy & Legal Officer.

Why It Matters

• This 8‑K notifies investors that REGENXBIO has released its quarterly financial results; the detailed figures and any management commentary appear in the attached press release (Exhibit 99.1).
• Investors should review the press release for key metrics (e.g., revenue, net income/loss, cash position) and any guidance or material changes, then follow up with the company’s earnings presentation or subsequent filings for deeper analysis.